Reference 9a
Nucleic Acid Amplification (NAA) testing in haemotological malignancy
Nucleic Acid Amplification (NAA) testing in haemotological malignancy
REFERENCE 09a (i)
Polymerase chain reaction (PCR) in the diagnosis and monitoring of chronic myeloid leukemia (CML)
REFERENCE 09a (ii)
Polymerase chain reaction (PCR) in the diagnosis and monitoring of acute promyelocytic leukemia (APL)
REFERENCE 09a (iii)
Polymerase chain reaction (PCR) in the diagnosis and monitroing of acute myeloid leukemia (AML)
REFERENCE 09a (iv)
Polymerase chain reaction (PCR) in the diagnosis and monitoring of acute lymphoblastic leukemia (ALL)
| Reference No. | 9a (incorporates i, ii, iii and iv) |
| Reference Name | Nucleic Acid Amplification (NAA) testing in haemotological malignancy |
| Advisory Panels | Professor Sydney Bell (Chair and MSAC member) Dr Paul Craft (MSAC member) Dr John Primrose (Medical Advisor to the MSAC until February 2002) Associate Professor Mark Hertzberg (Haemotology Society of Australia and New Zealand nominee) Associate Professor Harry Iland (co-opted member) Dr Paula Marlton (Royal College of Pathologists of Australasia nominee) Mr Michael Ralston (Pathology Services Table Committee) |
| Date Received by MSAC Secretariat | 1 October 2000 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | The MSAC recommended that on the strength of evidence pertaining to safety, effectiveness and cost-effectiveness of nucleic acid amplification testing in haemotological malignancies public funding should be supported for this procedure |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 22 June 2004 |
| Stage 5 - Implementation |  |
Page currency, Latest update: 30 March, 2009
